Gastrin Test · Blood

If your stomach lining is quietly thinning, if a medication is suppressing your acid too aggressively, or if a rare tumor is flooding your body with acid, your gastrin level will change before you feel anything. This single number reflects the ongoing conversation between your stomach's acid output and the cells that regulate it, giving you a window into stomach health that no standard blood panel includes.

Gastrin is a hormone produced mainly by specialized cells called G cells in the lower part of your stomach (the antrum). When your stomach acid drops, whether from food arriving, a medication suppressing acid, or damage to acid-producing cells, gastrin rises to signal "make more acid." When acid is plentiful, gastrin falls. A fasting gastrin level captures this feedback loop at rest and can reveal problems at both extremes: too much gastrin (hypergastrinemia) or too little.

What Gastrin Tells You About Your Stomach

Gastrin acts on cells deep in your stomach wall called enterochromaffin-like (ECL) cells, which release histamine, which in turn activates the acid-producing parietal cells. This chain reaction is the main pathway for gastric acid secretion. Gastrin also acts as a growth signal: it tells the stomach lining to maintain and expand the tissue responsible for making acid.

This dual role, controlling both acid output and cell growth, is what makes gastrin clinically interesting. A persistently high gastrin level does not just mean more acid. It means the stomach lining is being pushed to grow, and over years, that growth stimulation can lead to abnormal changes in the tissue.

Atrophic Gastritis and Stomach Cancer Risk

When the acid-producing part of the stomach (the corpus) is damaged, whether by an autoimmune attack or chronic Helicobacter pylori infection, the loss of acid-producing cells causes gastrin to rise dramatically. The body is trying to compensate for lost acidity, but the cells that would respond are gone. This creates a state of chronic hypergastrinemia that can persist for years.

In a prospective study of 282 patients with autoimmune atrophic gastritis followed over many years, higher gastrin levels tracked with more severe gastric damage, and more advanced disease stages carried a greater risk of developing gastric neuroendocrine tumors (a type of stomach growth driven by prolonged gastrin stimulation). The disease was steadily progressive: earlier stages always advanced to later ones.

When gastrin-17 (G-17, a specific form of gastrin) is combined with pepsinogens (proteins that reflect the health of the stomach lining) and H. pylori antibodies in a panel test, the combination detects atrophic gastritis with about 75% sensitivity and 96% specificity, meaning it catches roughly three out of four cases and very rarely flags someone who does not have the condition. Used alone, gastrin's sensitivity drops to around 37% to 48%, making it far less reliable as a standalone screen.

Gastrinoma and Zollinger-Ellison Syndrome

At the other extreme, a gastrin-secreting tumor (gastrinoma) produces massive amounts of gastrin, driving extreme acid output and severe ulcers. This condition, called Zollinger-Ellison syndrome (ZES), is rare but serious. Fasting gastrin levels in ZES are typically more than 10 times the upper limit of normal, combined with very low stomach pH (meaning the stomach is already full of acid, yet gastrin remains sky-high).

When baseline fasting gastrin is borderline rather than dramatically elevated, a secretin stimulation test can help distinguish a gastrinoma from other causes of mildly elevated gastrin. In this test, an intravenous dose of secretin is given, and gastrin is measured at intervals. A rise of 120 pg/mL or more has a sensitivity of 94% and a specificity of 100% for gastrinoma, meaning it catches nearly all true cases and never falsely diagnoses one.

In people with MEN1 (multiple endocrine neoplasia type 1), a hereditary condition that predisposes to gastrinomas, secretin-stimulated gastrin testing can detect tumors earlier than imaging can. If you have a family history of MEN1 or unexplained recurrent ulcers, this test can change the timing of diagnosis and treatment.

Gastrin as Part of Gastric Cancer Risk Scoring

In regions with high rates of stomach cancer, researchers have built risk scores that include gastrin-17 alongside pepsinogens and H. pylori status. A large Chinese prediction model (about 14,929 participants) categorized fasting G-17 into three tiers and assigned points within a 0 to 25 point score. People scoring 17 or above were classified as high risk for gastric cancer and referred for endoscopy. G-17 contributed meaningfully to the model but was not the dominant predictor on its own.

A cross-sectional study of 12,746 asymptomatic adults in coastal China confirmed that serum pepsinogens and G-17 vary systematically with H. pylori status, sex, and age, supporting their role as early markers of gastric pathology in population screening. Males had higher pepsinogen levels than females, and both pepsinogens and G-17 levels increased weakly with age.

Reference Ranges

There is no single universally accepted reference range for fasting serum gastrin. Values depend on the assay used, whether the test measures total gastrin or gastrin-17 specifically, and the population studied. The ranges below are drawn from published research and should be treated as orientation, not absolute targets. Your lab may report different numbers, and comparing results within the same lab over time is more meaningful than matching a single result to a published cutpoint.

In a study of 120 healthy Pakistani adults, the 2.5th to 97.5th percentile range for fasting serum G-17 was 2.31 to 49.36 pg/mL, measured using a specialized lab technique. These values were markedly different from Chinese reference ranges, confirming that ethnic and geographic variation matters. In a study of 982 patients attending endoscopy, the median fasting gastrin in patients with no infection, no PPI use, and no precancerous changes was 20 pM. PPI users had a median of 46 pM, while patients with precancerous conditions of the stomach body had a median of 48 pM (and up to 90 pM with concurrent PPI use).

Compare your results within the same lab over time for the most meaningful trend.

When Results Can Be Misleading

Several common factors can push your gastrin number up without indicating the conditions gastrin is designed to detect. Knowing these helps you avoid unnecessary alarm or, worse, missing a real problem because you assumed the elevation was benign.

• Proton pump inhibitors (PPIs): The most common confounder. Long-term PPI use raises gastrin to one to three times the upper limit of normal in most patients. In a systematic review of 16 studies (1,920 patients on PPIs for more than three years), mean gastrin levels consistently rose into this range. Levels normalize within about four weeks of stopping the medication. If you are taking a PPI, your gastrin result will be elevated and cannot be interpreted as a sign of disease without additional context.
• Kidney function: Gastrin depends heavily on kidney clearance. In dialysis patients, fasting gastrin averaged about four times higher than in healthy controls, with some individuals reaching levels that could mimic a gastrinoma. After kidney transplant, gastrin fell as kidney function improved. If your kidney function is reduced, your gastrin may be artificially high.
• H. pylori infection: Active infection modestly raises gastrin. In one large study, H. pylori-positive patients without precancerous changes had a median fasting gastrin of 27 pM compared to 20 pM in uninfected individuals. The combination of H. pylori and PPI use raises gastrin further and also increases the risk of corpus atrophy.
• Recent food intake: Gastrin rises after eating, especially after protein-rich meals. A fasting blood draw is essential for an interpretable result.

H2 receptor antagonists (like famotidine) and antacids do not appear to raise gastrin meaningfully. In a Swedish population study of 590 adults with normal gastric mucosa, H2 blocker users and antacid users had gastrin levels no different from non-users. Only PPI users showed the approximately doubled gastrin levels.

Sex and Age Effects

Women tend to have higher baseline fasting gastrin than men. In a study of 30 healthy volunteers, females had a median baseline gastrin of 12 pM compared to 7 pM in males. Among patients on long-term PPIs, women had median serum gastrin of 92 pg/mL versus 60 pg/mL in men. Female sex and higher PPI dose per kilogram of body weight both independently predicted greater gastrin elevation. Age is also an independent predictor: older individuals tend to have higher fasting gastrin and are more likely to develop hypergastrinemia on PPIs.